Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

Global and Regional Endoscopic Imaging Systems Market Analysis Report 2022-2030: Lucrative Opportunities with the Entry of Local Companies in Regional Endoscopic Imaging Systems Markets - ResearchAndMarkets.com


The "Endoscopic Imaging Systems Market - A Global and Regional Analysis: Focus on Product Type, Regional Analysis, and Country-Wise Analysis - Analysis and Forecast, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

The global endoscopic imaging systems market was valued at $3,641.3 million in 2021, and it is expected to grow with a CAGR of 7.43% and reach $6,941.3 million by 2030

The growth in the global endoscopic imaging systems market is expected to be driven by the growing adoption of minimally invasive procedures, the improving clinical quality of the endoscopic procedures, and the increasing technology integration in endoscopic imaging systems.

Market Lifecycle Stage

The endoscopic imaging systems market is an established market and has witnessed significant advancements over the past few years. The increasing demand for minimally invasive procedures will propel advancements in endoscopy and improve its adoption among end users such as physicians.

The adoption of artificial intelligence (AI) in endoscopic procedures and the entry of local companies into the regional endoscopic imaging systems market are significant opportunities in the global endoscopic imaging systems market. Moreover, the increasing demand in developing regions is also an opportunity for market growth.

Impact of COVID-19

The COVID-19 pandemic was an unprecedented event in the global healthcare system. Healthcare systems in various economies collapsed, and technology integration skyrocketed. The endoscopic procedures were impacted similarly during the initial phase of the pandemic. Several non-emergency procedures were delayed or canceled to minimize infection risk during the early months of 2020.

Similar to other medical specialties, the adoption rate was also negatively impacted in endoscopic imaging systems. The limited demand for new devices, high costs of endoscopic imaging systems, and disrupted supply chain were the major factors that hampered the production and sales of endoscopic imaging systems, specifically during the peak pandemic in 2020.

Nonetheless, during the forecast period 2022-2030, the device adoption rate is projected to normalize to pre-COVID-19 levels. The allocation of funds for purchasing new devices and the pace of procurement decisions would be the key factors impacting the device adoption rates.

The recurring waves of the COVID-19 pandemic might have a damaging impact on the sales of the devices. However, considering the growing demand for minimally invasive procedures and accelerated recovery period, the need for endoscopic procedures across various medical specialties is projected to grow.

The global endoscopic imaging systems market in the application segment is expected to be dominated by the diagnostic endoscopic imaging systems segment during the forecast period 2022-2030.

Recent Developments in Global Endoscopic Imaging Systems Market

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent players in this market are:

Key Topics Covered:

1 Market Definition

1.1 Product Definition

1.2 Inclusion and Exclusion

1.3 Forecast Period Selection Criteria

1.4 Assumptions and Limitations

2 Global Endoscopic Imaging Systems Market

2.1 Market Size and Forecast

2.2 Key Findings

3 Industry Outlook

3.1 Regulatory Framework

3.2 Impact of COVID-19 on Global Endoscopic Imaging Systems Market

3.2.1 Impact on Facilities

3.2.2 Impact on Device Adoption

3.3 Patent Filing Trends

3.3.1 By Year

3.3.2 By Country

3.3.3 By CPC Codes

3.3.4 By Key Companies

3.4 Key Enabling Technologies (Innovation Outlook)

4 Market Dynamics

4.1 Impact Analysis

4.2 Business Drivers

4.2.1 Growing Adoption of Minimally Invasive Procedures

4.2.2 Improving Clinical Quality Standards of the Endoscopic Procedures

4.2.3 Growing Technology Integration in Endoscopic Imaging Systems

4.3 Business Restraints

4.3.1 Dearth of Skilled Professionals

4.3.2 Lack of Reimbursement System in Developing Countries

4.4 Business Opportunities

4.4.1 Adoption of Artificial Intelligence in Endoscopic Procedures

4.4.2 Entry of Local Companies in Regional Endoscopic Imaging Systems Market

4.5 Market Trends

5 Global Endoscopic Imaging Systems Market (by Application)

5.1 Opportunity Assessment

5.2 Growth-Share Matrix

5.3 Diagnostic Endoscopic Imaging Systems

5.3.1 Market Size and Forecast

5.3.2 Unit Sold

5.3.3 Installed Base

5.4 Therapeutic Endoscopic Imaging Systems

5.4.1 Market Size and Forecast

5.4.2 Unit Sold

5.4.3 Installed Base

6 Region

For more information about this report visit https://www.researchandmarkets.com/r/g46fcw


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: